Theseus goes back to preclinical mode after axing lead targeted therapy over tolerability concerns, shares plummet

The­seus Phar­ma­ceu­ti­cals has run in­to dose-lim­it­ing tox­i­c­i­ties that’s forc­ing the com­pa­ny to aban­don its KIT in­hibitor, two months af­ter pre­sent­ing ini­tial da­ta on the pro­gram at AS­CO.

Re­searchers are wind­ing down the on­go­ing Phase I/II study and end­ing the de­vel­op­ment of THE-630 in pa­tients with gas­troin­testi­nal stro­mal tu­mors (GIST) al­to­geth­er af­ter in­ves­ti­ga­tors flagged two cas­es of hand-foot skin re­ac­tion out of six pa­tients who got a 27 mg dose.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN